{"slug":"ss-31-gut","verification":{"valid":true,"entries":1,"head":"477ff55f9f6d0b3c8c8382d42e046a19f441e73c6f756acd9f459e0d6d360c3c"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.052098,"waste_cost_usd":0,"total_tokens":38890,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.052098,"tokens_total":38890,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:54:01.705Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) Mitochondrial Support for Gut: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nGut barrier integrity depends on intestinal epithelial cells maintaining tight junctions and low oxidative stress. Mitochondrial dysfunction in these cells can increase reactive oxygen species, disrupt cardiolipin in the inner membrane, impair ATP production, and trigger apoptosis. This process weakens tight junction proteins such as ZO-1 and occludin. The result is higher paracellular permeability. Repair pathways that stabilize mitochondria can address the root layer rather than only downstream inflammation or symptoms.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial oxidative stress and cardiolipin instability form part of your gut barrier challenge, SS-31 (Elamipretide) is discussed because it binds cardiolipin directly. Step one: the peptide accumulates in the inner mitochondrial membrane. Step two: it stabilizes cristae structure and supports electron transport chain efficiency. Step three: this reduces electron leak and ROS production while preserving ATP output. Step four: lower ROS can limit apoptosis and support maintenance of tight junction proteins. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\n## How these fit together\n\nSingle-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer of intestinal epithelial cell health. No sibling peptides are in scope for this review.\n\n## What the evidence actually shows\n\nHuman data specific to gut: none identified. Preclinical data: one in-vitro study examined mycophenolic acid (MPA)-induced damage in intestinal epithelial cells. MPA increased ROS, reduced tight junction expression, and raised apoptosis. SS-31 treatment lowered intracellular and intramitochondrial ROS, upregulated tight junction proteins, and reduced apoptosis rates (preclinical tier, Deng et al. 2022, PMC9277164). Multiple rodent LPS models (LPS models systemic inflammation often linked to gut-derived endotoxins) showed SS-31 preserved mitochondrial membrane potential, reduced hippocampal oxidative stress, and improved behavioral outcomes, but these did not measure intestinal barrier endpoints directly (preclinical tier, Zhao et al. 2019). Broader mitochondrial studies in kidney and heart models confirm cardiolipin stabilization and ROS reduction in animal tissue (preclinical tier). No randomized human trials report gut permeability, microbiome, or intestinal histology outcomes.\n\n## What scientists say\n\nResearchers describe SS-31 as a cardiolipin-targeting tetrapeptide that improves bioenergetics without acting as a general antioxidant. Reviews note consistent mitochondrial protection across cell types in culture and rodents, with emphasis on cristae preservation and reduced cytochrome c release. Clinical development has focused on primary mitochondrial myopathy, heart failure, and Barth syndrome; gut-specific applications remain exploratory (mechanistic tier, multiple reviews 2024-2025).\n\n## What people say on Reddit\n\nAnecdotal reports in CFS and ME/CFS communities mention SS-31 primarily for energy and cognitive function. Some users note transient GI symptoms (nausea, diarrhea, hot flashes) during initial dosing that later resolved; others report no gut-specific benefits or changes. One user described fixing digestion first with other interventions before adding SS-31 for mitochondrial support (anecdotal tier, r/cfs threads 2025).\n\n## What people say on X\n\nLimited public discussion. Posts focus on mitochondrial medicine in general or Barth syndrome approval rather than gut outcomes. No widespread user reports tie SS-31 directly to intestinal barrier improvements (anecdotal tier).\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy data exist for intestinal epithelial mitochondria or gut permeability. Duration of effect on tight junctions, interactions with microbiome composition, and long-term outcomes in chronic gut conditions remain unstudied in controlled settings. Dose-response relationships specific to gut tissue are unknown.\n\n## Safety and limits\n\nHuman trials in non-gut indications report good short-term tolerability with injection-site reactions as the main observation. Some preclinical and anecdotal sources note possible transient GI distress. Long-term human safety beyond trial durations is not established. Evidence for gut applications rests entirely on mechanistic and limited preclinical layers.","claims":[{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes cristae structure.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Core mechanism explaining potential intestinal epithelial support","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In an in-vitro model, SS-31 reduced MPA-induced ROS, upregulated tight junction proteins, and lowered apoptosis in intestinal epithelial cells.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Only direct gut-related preclinical finding identified","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials report effects of SS-31 on gut barrier function, permeability, or intestinal histology.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies absence of clinical gut data","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"LPS rodent models show SS-31 preserves mitochondrial function under inflammatory stress, though gut barrier endpoints were not measured.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Supports mitochondrial layer relevance via LPS (gut-derived endotoxin model)","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:54:01.331Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.mdpi.com/1422-0067/26/3/944","title":"Elamipretide: A Review of Its Structure, Mechanism, and Therapeutic Potential","quote":"Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin (CL) on the inner mitochondrial membrane","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9277164/","title":"Mycophenolic Acid Induces the Intestinal Epithelial Barrier Dysfunction","quote":"These results suggest that SS-31 protects the intestinal mechanical barrier and reduces apoptosis in vitro by inhibiting MPA-induced oxidative stress.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"review","url":"https://www.innerbody.com/ss-31-peptide","title":"SS-31 Peptide | Benefits, Safety & Buying Advice [2026]","quote":"Human trials focus on mitochondrial myopathy, heart failure, and renal artery stenosis; no gut-specific outcomes reported.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice","quote":"Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":36102,"tokens_out":2788,"cost":0.0520975,"prev_hash":"genesis","hash":"477ff55f9f6d0b3c8c8382d42e046a19f441e73c6f756acd9f459e0d6d360c3c"}]}